Notably, methylation of the DKK3 promoter was recently shown to be prognosis relevant also in other tumor entities, such as in acute lymphoblastic leukemia, kidney cancer, lung cancer, and gastric cancer [21-24], pointing to a potential clinical use of this marker in several cancer diseases. This evidence concerns the gene DKK3 and lung carcinoma.